Company: Boehringer Ingelheim
Job title: Senior Vice President & Research Site Head Austria
Darryl McConnell is currently Senior Vice President and Research Site Head at Boehringer-Ingelheim Regional Centre Vienna, Austria. His goal is to discover new chemical therapeutics for cancer’s so-called undruggable targets together with the team at BI. Darryl’s interests lie in drugging protein-protein interactions, kinases and pushing the frontiers of PROTACs for cancer patients. Fragment screening, protein crystallography, protein NMR, drug resistance, agile methods in drug discovery and natural product inspired medicinal chemistry are some of his areas of scientific interest. Darryl commenced his career with Boehringer-Ingelheim in 2002 as a Research Laboratory Head and is in his current role since 2015. Prior to this Darryl has worked for Intervet in Vienna from 2001, for Biota Holdings Ltd in Melbourne, Australia from 1999 in the area of respiratory viruses and Chiron Technologies in Melbourne from 1997. Darryl McConnell received his Bachelor of Science with First Class Honours in 1991 with Professor John Elix at the Australian National University in Canberra. He performed his PhD at the University of New South Wales in Sydney with Professor David Black for which he was awarded the Cornforth Medal for the best chemistry PhD thesis in Australia for that year. Following this he performed a 2 year Postdoctoral study at the University of Sydney with Professor Leslie Field in organometallic chemistry.
Drugging the Other KRAS Mutants 10:00 am
• Boehringer Ingelheim is taking a systematic approach to discovering drugs for all KRAS mutants • The potential approaches to drugging KRAS beyond G12C with small molecules will be discussed • Highlights from some of Boehringer Ingelheim’s KRAS programs will be presentedRead more
day: Day One